Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00517868 · ClinicalTrials.gov registry record · Phase 2
Study of URG101 in Painful Bladder Syndrome and Interstitial Cystitis
A Phase 2 study, sponsored by Urigen.
- Terminated
- Registry status
- Phase 2
- Development phase
- 28
- Enrollment target
NCT00517868 is a Phase 2 study that was terminated before completion, run by Urigen. The registered enrollment target is 28 participants.
The verdict
NCT00517868, a Phase 2 study, was terminated before completion, sponsored by Urigen.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 28 participants
- Enrollment target
Study Summary
A double-blind, placebo-controlled study to evaluate changes in pain, urgency and urinary frequency following administration of URG101 compared to placebo.
Interventions
- DRUG Placebo
- DRUG URG101
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 28 participants |
| Start Date | 2007-08-28 |
| Est. Completion | 2008-02-28 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00517868
The ClinicalTrials.gov registry entry for NCT00517868 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 28 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Urigen, which has 3 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT00517868 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00517868 about?
NCT00517868 is a clinical study titled "Study of URG101 in Painful Bladder Syndrome and Interstitial Cystitis". A double-blind, placebo-controlled study to evaluate changes in pain, urgency and urinary frequency following administration of URG101 compared to placebo.
What is the current status of trial NCT00517868?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 28 participants. The study started on 2007-08-28. Estimated completion is 2008-02-28.
What interventions are being tested in trial NCT00517868?
The interventions under investigation include: Placebo (DRUG), URG101 (DRUG).
Who is sponsoring clinical trial NCT00517868?
This trial is sponsored by Urigen, which has 3 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.